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Abstract
Background: During clinical practice, we noticed that some patients with both ulcerative colitis
(UC) and chronic rhinosinusitis (CRS) showed amelioration of UC after treatment of CRS. This
study was designed to identify a possible association between CRS and UC.
Methods:  Thirty-two patients with both CRS and UC received treatment with functional
endoscopic sinus surgery (FESS) for CRS. Clinical symptom scores for CRS and UC, as well as
serum levels of anti-Staphylococcal enterotoxin B (SEB) were evaluated at week 0 and week 12.
Sinus wash fluid SEB content was measured with enzyme-linked immunosorbent assay (ELISA). The
surgically removed tissues were cultured to identify growth of Staphylococcus. aureus (S. aureus).
Immunohistochemistry was employed to identify anti-SEB positive cells in the colonic mucosa.
Colonic biopsies were obtained and incubated with SEB. Mast cell activation in the colonic mucosa
in response to incubation with SEB was observed with electron microscopy and immunoassay.
Results: The clinical symptom scores of CRS and UC severe scores (UCSS) were significantly
reduced in the UC-CRS patients after FESS. The number of cultured S. aureus colonies from the
surgically removed sinus mucosa significantly correlated with the decrease in UCSS. High levels of
SEB were detected in the sinus wash fluids of the patients with UC-CRS. Histamine and tryptase
release was significantly higher in the culture supernate in the patients with UC-CRS than the
patients with UC-only and normal controls. Anti-SEB positive cells were located in the colonic
mucosa.
Conclusion: The pathogenesis of UC in some patients may be associated with their pre-existing
CRS by a mechanism of swallowing sinusitis-derived SEB. We speculate that SEB initiates
inappropriate immune reactions and inflammation in the colonic mucosa that further progresses to
UC.
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Background
Ulcerative colitis (UC) is a relapsing chronic inflamma-
tory disease of the colon with unknown etiology. The evi-
dence from animal models suggests that an altered
immune response towards the commensal gut microbiota
plays a key role in the development and perpetuation of
this pathological condition [1,2]. Treatment of UC is still
a hot topic in clinical research. Although therapeutics has
been advanced greatly in the recent years [3-5], generally
inflammatory suppression with glucocorticoids and/or
sulfasalazine is still the primary therapy for UC [6,7].
However, a large number of patients are resistant or intol-
erant to medical treatment [8].
The accumulation of evidence from animal studies, cell
culture studies, and clinical observations has indicated an
important role for microbes and/or their products in the
induction or exacerbation of enterocolitis [9]. Microbial
antigen Staphylacoccal enterotoxin B (SEB) has been
shown to induce enteropathy, characterized by altered vil-
lus-crypt in BALB/c and T cell-reconstitued SCID mice
[10]. Oral feeding of SEB leads the development of colitis
in the absence of regulatory T cells [11]. SEB has been
shown to cross the intestinal epithelial cell barrier [12]
and is implicated in inducing inappropriate immune reac-
tions in humans [13] and mice [14] leading to activation
of T cells to produce proinflammatory cytokines such as
IL-1, IL-2, TNF-α and IFN-γ [15,16]. SEB is capable of
inducing inflammatory cytokines release from explants of
colonic biopsies from patients with IBD [17]. However,
our knowledge about the association between SEB and
IBD is still limited. SEB is synthesized as a precursor pro-
tein of 266 amino acids. This precursor is then activated
during excretion by cleavage of the N-terminal portion of
the molecule. The active enterotoxin B is a single 239
amino acid chain of molecular weight 28,000 Daltons
and isoelectric point of 8.6 [18]. SEB is a superantigen and
possesses powerful immune regulatory capabilities that
result in increased T cell activation and proliferation. SEB-
treated Balb/c mice display a dose-dependent colonic
inflammation [19]. SEB can also induce colonic epithelial
barrier dysfunction [20] that promotes uptake of exoge-
nous antigens [21], microbial products and other noxious
substances into the intestinal tissue to contact immune
cells and to initiate immune reactions.
Over the past 15 years, more than 2000 patients with
chronic rhinosinusitis (CRS) including some patients
with both CRS and UC (UC-CRS) visited our clinic. Their
CRS was treated with different remedies, including medi-
cal treatment and functional sinus endoscopic surgery
(FESS). Apart from the satisfactory efficacy in the treat-
ment of CRS, some of the patients with UC-CRS showed
great amelioration of UC as well that couldn't be
explained with the primary treatment alone. Therefore, we
postulated that there might be an association between
CRS and UC in these patients. Microbial infection is the
most common cause of CRS. The microbial products pro-
duced in the sinuses, such as SEB [22,23] can be dis-
charged into the nasal cavity with secretions through the
natural ostia going backward to the pharynx, and then
swallowed. After reaching the gastrointestinal tract, SEB is
capable of affecting intestinal mucosal physiological func-
tions [24,25]. Therefore, this prospective study was
designed to identify a possible association between CRS
and UC.
The nasal cavity and sinus are primary sites of coloniza-
tion by S. aureus [26], and SEB was detected in the nasal
cavity of the patients with CRS, nasal polyposis and aller-
gic rhinitis [22,23,27,28]. Based on clinical observations,
we hypothesized that sinusitis-derived SEB played a role
in the pathogenesis of chronic inflammation in the intes-
tinal mucosa via impairing the epithelial barrier function
and inducing inappropriate immune reactions. In this
study, we aimed to investigate if (i) colonization of S.
aureus can be identified in the sinus cavity of the patients
with UC-CRS; (ii) SEB production can be detected in the
sinuses; (iii) the improvement of UC associates with the
removal of inflammation from the sinuses; (iv) immune
cells in the colonic mucosa have been and can be activated
by SEB.
Methods
In this study, we evaluated the effect of FESS in the treat-
ment of a group of patients with refractory CRS and mod-
erate UC. The study protocol was approved by the
research ethics committee at the First Hospital, Shanxi
Medical University. All patients gave written informed
consent prior to recruitment. Surgical intervention was
chosen for the patients because they had tried different
therapies that failed to cure their CRS. The clinical condi-
tion of UC was moderate and suitable for sinus surgery.
Those patients with severe UC were excluded. Unless oth-
erwise mentioned, all the reagents used in this study were
purchased from Sigma Aldrich (USA).
Thirty two patients with refractory CRS and moderate UC
were enrolled in this study. Another 32 patients with
moderate UC but no CRS were selected as a control group.
Twenty-five healthy medical students were enrolled in this
study as a healthy control group, their serum and nasal
wash fluids were collected as controls. We diagnosed CRS
as inflammation of the sinus mucosa with a persistent
mucoid or mucopurulent nasal discharge for longer than
3 months that resisted antimicrobial therapy and antral
irrigation. Diagnosis was made on the basis of clinical his-
tory, rhinoscopic findings, and computed tomographic
scan of rhinosinuses. CRS was confirmed by computed
tomographic examination that showed diffuse mucosalBMC Gastroenterology 2005, 5:28 http://www.biomedcentral.com/1471-230X/5/28
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thickening in the ethmoid or/and maxillary sinuses bilat-
erally with scores higher than 12 by the Lund-Mackay
staging system [29].
The diagnosis and treatment of UC was carried out by one
gastroenterologist (Dr An Z). The diagnosis of UC [30]
was based on clinical history, colonoscopy and histology.
The history included persistent bloody diarrhea, rectal
urgency, or tenesmus, stool. Examinations, sigmoidos-
copy and biopsy were performed to confirm the presence
of colitis and to exclude the presence of infectious etiolo-
gies. UC severity scores (UCSS) [31] were recorded for
each patient on admission (week 0) and week 12. The
UCSS were evaluated from 4 clinical items: stool fre-
quency, rectal bleeding, sigmoidoscopic appearance, and
the physician's global assessment.
Sinus and nasal wash fluids collection
Every patient with UC-CRS underwent maxillary sinus
puncturing and irrigating with saline. The SWF was col-
lected prior to other procedures. Five ml saline was
injected into the sinus cavity and recollected and stored at
-70°C for further analysis. Protein content in SWF was
evaluated with UV spectrophotometer (Beckman DU-65)
at 280 nm. Contents of SEB, SEA and TSST1 in SWF were
evaluated with ELISA. Nasal lavage fluids (5 ml saline)
instead of sinus irrigation were collected from the healthy
controls and UC controls. None of the subjects had acute
upper respiratory acute infections within the past month.
Treatment
The procedures of FESS followed the previous reports
[32]. Penicillin G (800,000 IU, i.m., Bid) was adminis-
tered after the surgery for 3 days (no patient in this group
showed allergic signs for penicillin G). The surgical side of
sinus was irrigated daily until the irrigated fluids became
clear. After discharge, the patients were required to visit
the hospital to conduct a post-operation examination of
nasal cavity and sinuses on a monthly basis for the first
year. Any unusual feelings in the operated sinus area were
recorded. Physicians would do necessary treatment for
relapse of inflammation in the sinuses during the entire
follow-up period. The treatment of UC including sul-
fasalazine and corticosteroids continued for each patient
during the 12-week observation period including the
patients with UC-CRS and the patients with UC.
Serology of C-reaction protein, IgE and cytokines
Blood samples were collected at week 0 and week 12. The
serum was separated and analyzed for contents of C reac-
tive protein and SEB specific IgE respectively. The meth-
ods were done as previously reported. [33,34] Blood
samples were also collected from the healthy controls and
UC-controls twice, 12 weeks apart.
S. aureus identification
Surgically removed tissues were obtained from each
patient (a nasal lateral wall swab was obtained from UC-
only patients and healthy controls instead) and were sent
to the Microbiological Laboratory within 30 minutes. 100
mg mucosa was homogenized in 0.1 ml saline. The same
volume of the homogenates from each patient was cul-
tured aerobically on blood agar plates. Colonies of differ-
ent morphology growing on the agar were separately
enumerated, subcultured on blood agar, Gram stained,
and tested for catalase production. Isolates with a typical
Gram-stained appearance and a positive catalase test were
tested for coagulase production, and positive isolates were
regarded as S. aureus. The template DNA was extracted
from the positive cultured colony of each subject with the
procedures reported by Riffon [35]. PCR was performed
with the samples from each subject. The nucleotide
sequence is available at the GenBank data library (acces-
sion number, CP000046). The primers were designed
using the software Primer3 and the specificity was deter-
mined with Blast. The primers were: 5'-ttgcatatccgcgt-
caaata-3' and 5'-cttcatgttctttcgcatcg-3'. Amplification was
performed on a Perkin-Elmer (Norwalk, Conn.) thermo-
cycler in 25-µl reaction mixtures. The program consisted
of an initial denaturation step at 94°C for 2 min, followed
by 22 cycles of 1 s at 94°C, 2 s at 58°C, and 10 s at 72°C,
with a final extension step at 72°C for 5 min. Amplifica-
tion products were separated on a 1% agarose gel and
stained with ethidium bromide before being analyzed on
a UV bench by using GelDoc2000 (Bio-Rad). The PCR
products were routinely sequenced to confirm amplifica-
tion of the targeted sequence.
Immunohistochemistry
Two pieces of colonic tissue at the edge of ulcers was taken
during colonoscopy from each patient. One biopsy was
snap frozen with liquid nitrogen in Tissue Tek. Cryosec-
tions were air dried overnight and fixed with cold acetone
for 15 minutes. The endogenous peroxidase was
quenched by incubation in 0.3% H2O2 for 30 minutes
and non-specific binding was blocked by incubating the
sections in 10% goat serum/phosphate-buffered saline.
Specimens were incubated with mouse anti-SEB mono-
clonal antibody or IgG isotype control immunoglobulin.
Subsequently, after incubation with secondary rabbit anti-
mouse antibody (HRP conjugated, Vector Laboratories),
color was developed applying the Vectastain peroxidase
detection kit and diaminobenzidine as a substrate. Coun-
terstaining was performed with hematoxylin. The negative
control slides omitted the first antibody or added the iso-
type control instead.BMC Gastroenterology 2005, 5:28 http://www.biomedcentral.com/1471-230X/5/28
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Tryptase and histamine release from the cultured colonic 
biopsies in response to the stimulation of SEB
One of the two intestinal biopsy specimens from each
patient was subjected to histamine and tryptase release
evaluation in response to SEB stimulation. Briefly, upon
removal, the specimens were weighed in a sterile vial con-
taining 1 ml pre-warmed (37°C) and oxygenized RPMI
1640 culture medium (no serum). The specimen contain-
ing vials were incubated for 30 minutes at 37°C in a
humidified 95% and air containing 5% CO2 atmosphere
and environment and rocked gently at 20 cycles/min. The
supernatants were carefully collected and temporally kept
at 4°C. The specimens were washed with pre-warmed no-
serum RPMI medium for 3 times, then another RPMI
1640 medium (no serum) with 20 µl SEB/ml was added
to the vial and incubated for another 30 minutes. The
colonic tissues were carefully taken out and immersed to
2% glutaraldehyde immediately. The supernatants were
centrifuged at 17,530 × g for 10 minutes at 4°C. The
supernatants were stored at -70°C for further assay. Eight
mucosal specimens from surgical removed colonic tissue
of the patients with colonic cancer were collected. Sam-
ples were selected from the uninvolved part and processed
as normal controls.
For tryptase activity assay, triplicate aliquots (10 µL) of the
supernatants were added to 200 µL of buffer (50 mmol/L
Tris/HCl, pH 7.6, 120 mmol/L NaCl, 20 µg/mL heparin)
containing 0.5 mmol/L substrate (tosyl-Glycine-Proline-
Arginine-pNitroanilide) and incubated at room tempera-
ture for 17 hours (± inhibitors as indicated). Cleavage of
the substrate was measured using a microtiter plate reader
(absorbance 405 nm) and normalized to the weight of the
biopsy specimens used in each specimen.
For histamine assay, triplicate aliquots (50 µL) of the
supernatants using a selective enzyme-linked immu-
noassay (Immunotech, Marseille, France) according to the
manufacturer's directions. Histamine was measured using
a microtiter plate reader (absorbance 405 nm) and nor-
malized to the weight of the biopsy specimens.
Electron microscopy
After incubation with SEB, the colonic biopsies were fixed
with 2% glutaraldehyde for 2 hours at room temperature
and postfixed in 1% osmium tetroxide for 1 hour. After
dehydration and embedding in EPON, ultra thin section
were cut and collected on 200 mesh grids, stained with
uranyl acetate and lead citrate, and observed with a JEC
1200 transmission electron microscope. Thirty mast cells
were selected randomly from each specimen and photo-
graphed. The granules of the selected mast cells were cate-
gorized into three types: intact, piecemeal degranulation
(PMD) and anaphylactic degranulation (AND) according
to reported criteria [36].
Statistical analysis
Data were expressed as means ± standard deviation (SD).
Differences between groups were analyzed with the stu-
dent t test or χ2 test. Correlationship between groups was
demonstrated by correlation analyses. The significant cri-
teria was set at p < 0.05.
Results
Clinical symptoms of CRS improved after FESS
All the CRS patients underwent FESS in their maxillary
sinusitis. Twelve (37.5%) patients also underwent bilat-
eral ethmoidectomy. Eight patients also underwent uni-
lateral ethmoidectory (25%, right or left side). Four
(12.5%) patients also underwent septum orthomorphia.
Fourteen (43.75%) patients had nasal polyps that were
removed during FESS. Five (15.63%) patients underwent
partial middle turbinectomy. Six (18.75%) patients
underwent inferior turbinectomy. During the 12-week
observation period, all the patients underwent regular fol-
low-up visit (The total follow-up period lasted for one
year after FESS). Twelve weeks after FESS, all the patients
reported significant improvement in their clinical symp-
toms of CRS. Clinical symptom scores were recorded at
week 0 and week 12 that were defined from 0 to 4. 0 for
no symptoms; 4 for severe. Most patients had moderate to
severe CRS clinical symptoms before FESS; 29 out of 32
(90.62%, scored 0 and 1) patients showed significant
reduction of their clinical scores of sinusitis; 21 out of 32
(65.63%) scored 0 and 1 (Fig 1).
Effect of treatment with FESS on UC clinical symptoms
The demographic characteristics of the patients in the
present study are listed in Table 1. In the period of 12
week observation period, treatment for UC of the patients
in this study were carried out by one gastroenterologist
according to routine therapy. After FESS, the requirement
for steroids was gradually reduced in the UC-CRS group
and was significantly less than the UC group (Fig 2). From
week 0 to week 12, levels of C reactive protein rose in con-
trol patients (with UC only) who received routine treat-
ment rather than FESS, from 4 to 20 mg/l, whereas the
value reduced significantly in the FESS group. The C reac-
tive protein in the healthy control group was under detect-
able levels (Fig 3).
Sigmoidoscopy was performed in all subjects during
admission and 12 weeks after FESS. The control UC
patients were also examined with sigmoidoscopy in the
same period. The results showed that the patients with
both UC-CRS significantly improved in appearance of the
colonic mucosa after FESS, while UC patients showed no
change. UCSS assessment also showed significant
improvement in the patients with UC-CRS after FESS. The
UCSS did not show much difference in the patients withBMC Gastroenterology 2005, 5:28 http://www.biomedcentral.com/1471-230X/5/28
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UC-only although they received the routine treatment for
their UC (Fig 4).
S. aureus was identified in the sinuses of the patients with 
CRS
Bacterial culture results showed S. aureus growth in the
surgically removed tissue in 24 (75%) patients with UC-
CRS. The numbers of S. aureus colonies in the culture
ranged from 0 to 76 with an average of 28.5/patient. The
reduction of UC clinical symptom scores significantly cor-
related with the number of the cultured S. aureus colonies
from the surgical removed sinus mucosa (Fig 5, r =
0.8399, p < 0.0001). PCR results showed S. aureus DNA
amplified products from the surgical removed tissue of 32
(100%) patients that further confirmed the existence of S.
aureus infection in the sinuses of patients with UC-CRS
(Fig 6). RT-PCR amplified product sequence analysis con-
firmed that the amplified bands were consistent with the
target DNA sequences. Fig 7 depictes serum IgE assay
results. Serum specific IgE and total IgE levels were evalu-
ated with ELISA. Before FESS, serum anti-SEB antibody
levels were significantly higher in the patients with UC-
CRS than the patients with UC only and the healthy con-
trols (p < 0.05). The levels of specific IgE in UC-CRS
patients were significantly decreased as measured at week
12 after FESS (p < 0.05). The levels of total IgE were also
higher in UC-CRS patients before FESS compared with
UC-only patients and healthy controls (p < 0.05). The
results showed the total IgE levels were also significantly
decreased after FESS as compared with the results before
FESS (p < 0.05). A ratio of specific IgE/total IgE was calcu-
lated and listed as: control group (28.6% and 15.6%;
week 0 and week 12); UC-only group (10.6% and 8.8%)
and UC-CRS group (26.3% and 23.5%). Ratio statistical
analysis showed that differences between week 0 and
week 12 didn't reach significance (p > 0.05) in all three
groups indicating the same tendency of change in total IgE
and the SEB specific IgE.
Chronic rhinosinusitis clinical scores of the patients with both chronic rhinosinusitis (CRS) and ulcerative colitis (UC) was  recorded before (week 0, A) and after (week 12, B) FESS Figure 1
Chronic rhinosinusitis clinical scores of the patients with both chronic rhinosinusitis (CRS) and ulcerative colitis (UC) was 
recorded before (week 0, A) and after (week 12, B) FESS. 0 stands no symptom; 4 stands severe symptom. The numbers stand 
for clinical scores (percentage of patient). The results of χ2 analyses showed p < 0.05 as compared the clinical scores of week 0 
with that of week 12.
Table 1: Demographic and disease features of the patients before FESS
Group Control FESS
Sex Male: 15; female: 17 Male: 18; female: 14
Age 33.23 (20 – 66) 35.82 (26 – 58)
Weight (kg) 62 (55 – 68) 60 (51 – 71)
Duration of UC (months) 28 (15 – 68) 35 (29 – 78)
Prednisolone equivalent (mg/day) 15 (5 – 20) 15 (5 – 20)
Data are shown as medians (interquartile ranges). UC, ulcerative colitis; FESS: functional endoscopic sinus surgery.
2 (6.3%)
3( 1 8 . 7 % )
4( 7 5 % )
A
0( 8 1 . 2 % )
1 (9.4%)
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Page 6 of 14
(page number not for citation purposes)
SEB specific antibody positive stained cells were located in 
the colonic mucosa. High concentration of SEB was 
evaluated in the sinus wash fluids
Immunohistochemistry showed anti-SEB positive stain-
ing cells in the colonic mucosa of patients with UC-CRS,
but not in patients with UC only (Fig 8). Sinus wash fluids
were evaluated for SEB content. A significantly higher SEB
level was found in the sinus wash fluids from patients
with UC-CRS. SEB content was much lower in the nasal
wash fluids of the UC-only patients and healthy controls.
Sinus wash fluids were also colleted from 12 patients with
CRS, but without UC and 12 patients with nasal polyposis
and CRS, but without UC at week 0 and week 12 after
FESS. SEB content in the sinus wash fluids was also evalu-
ated (Fig 9). The contents of SEA and TSST1 in the sinus
wash fluids were undetectable.
Colonic mucosal mast cell degranulation in response to 
SEB stimulation ex vivo
The numbers of mast cells in the colonic mucosa were
counted with light microscopy. There were significantly
more mast cells in patients with UC-only and UC-CRS
compared with normal control colonic mucosa. As
depicted in Figures 10 and 11, electron microscopy
revealed three types of granules in the mast cells of the
colonic mucosa, intact, PMD and AND. In the normal
colonic mucosa, there was a low ratio of degranulation in
the colonic mast cells (PMD, 7.7 ± 4.2%; AND, 2.2 ±
3.1%). A significant increase in the ratio of degranulation
of both PMD and AND was observed in colonic speci-
mens of patients with UC-only and UC-CRS before SEB
stimulation. A great difference was observed in the mast
cell degranulation in the colonic mucosa in response to
SEB stimulation between the groups with UC only and
Prednisolone requirement was recorded from the patients with UC-CRS and the patients with UC at week 0 (A) and week 12  (B) Figure 2
Prednisolone requirement was recorded from the patients with UC-CRS and the patients with UC at week 0 (A) and week 12 
(B). The bars represent the number of patients. χ2 analyses were performed with the data between the two groups. The 
results showed p > 0.05 at week 0 and p < 0.05 at week 12.
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UC-CRS ex vivo. AND type degranulation was
significantly increased in patients with UC-CRS compared
to UC only patients (p < 0.05).
Tryptase and histamine release in response to SEB 
stimulation ex vivo
Tryptase and histamine was detected in the culture of the
colonic biopsies in the first 30-minute. The levels of tryp-
tase and histamine were approximately 3 times higher in
the specimens from patients with UC or UC-CRS com-
pared to normal controls. The release of tryptase and his-
tamine further increased after incubation with SEB in the
Ulcerative colitis severe scores of the patients with UC-CRS and the patients with UC-only were recorded at week 0 (A) and  week 12 (B) Figure 4
Ulcerative colitis severe scores of the patients with UC-CRS and the patients with UC-only were recorded at week 0 (A) and 
week 12 (B). Bars represent summary scores from clinical observation. Data were presented as numbers of patients of each 
score. χ2 analyses were performed with the data between the two groups. The results showed p > 0.05 at week 0 and p < 0.05 
at week 12.
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S. aureus was cultured with the surgical removed sinus  mucosa of the patients with UC-CRS Figure 5
S. aureus was cultured with the surgical removed sinus 
mucosa of the patients with UC-CRS. The method using to 
identify S. aureus was described in the text. Bars stand for 
numbers of patients.
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UC-CRS group, but not in the UC group. The tryptase
inhibitor BABIM significantly inhibited the effect of tryp-
tase (Fig 12).
Discussion
We have observed the clinical outcome of a group of
patients with both CRS and UC after treatment with FESS.
Clinical symptom scores of both CRS and UC were signif-
icantly reduced 12 weeks after FESS. UC-CRS patients
exhibited sinus infection with S. aureus high levels of anti-
SEB antibody in the serum, and anti-SEB antibody posi-
tive stained cells in the colonic mucosa. In particular, the
mast cells in the colonic biopsy specimens from the
patients with UC-CRS were activated by incubation with
SEB by showing extensive degranulation and release of
histamine and tryptase. This is consistent with Dionne's
Serum IgE antibody Figure 7
Serum IgE antibody. Serum samples were collected from all the subjects at week 0 and week 12. IgE levels were evaluated with 
ELISA. Data were presented as mean ± SD. *, p < 0.05, compared with the same group at week 0. A, serum total IgE; B, serum 
anti-SEB IgE.
Anti-SEB positive stained cells were located in the colonic mucosa Figure 8
Anti-SEB positive stained cells were located in the colonic mucosa. Colonic biopsies were got from the patients with UC-only 
(A) and the patients with UC-CRS (B and C). Cryosections were stained with anti-SEB antibody or IgG isotype control immu-
noglobulin (B). Sections were visualized by the immunoperoxidase method and counterstained with hematoxylin. SEB specific 
IgE-bearing cells were stained in brown (C). ×200.
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study [17] that reported SEB induced IBD rectal biopsies
to release inflammatory mediators ex vivo such as TNF-α
and IL-1.
During the 12-week observation period, both groups of
UC patients with or without CRS were treated with the
routine remedies for UC, mainly sulfasalazine and
glucosteroids. Therefore, the marked improvement of UC
in patients with UC-CRS should be the removal of inflam-
mation in the sinuses by FESS. Although brief (3 days)
penicillin G administration was given to patients after
FESS, it did not likely contribute to the amelioration of
UC, because penicillin G mainly effects on acute Gram
positive bacterial infection which grow fast and have high
requirement of cell wall synthesis whereas UC is a chronic
inflammatory disease. The prevalence of Crohn's disease,
another form of IBD, was elevated in patients with
chronic sinonasal disease, occurring in approximately
one-half of patients followed at a tertiary IBD center [37].
Chronic rhinosinusitis is a multi-variant disease. Bacterial
infection is the accepted cause of acute sinusitis in most
circumstances, but the causes of chronic sinusitis are more
complicated. S. aureus is a common pathogen that con-
tributes to both acute and chronic rhinosinusitis [38]. The
present study has added supportive data to the observa-
tion above. We identified S. aureus in the surgically
removed tissues from the sinuses in 75% of the patients
with UC-CRS and 100% of sinus samples showed positive
mRNA for S. aureus. One of the features of CRS is purulent
secretions into nasal cavity via the natural ostia. The nasal
mucosa is covered with a lining of ciliated epithelium,
covers with mucus blanket. One of the functions of this
mucus blanket is the trapping of dust from inhaled air and
secretions from the sinuses, and removing them from the
nasal cavity by rhythmic locomotion. Because of the back-
ward movement of the mucus blanket, some of the
trapped substances such as SEB may be swallowed and
enter the gastrointestinal tract to alter the mucosal
physiological functions. The present data show high levels
of SEB in the sinus wash fluids from the patients with UC-
CRS. Previous reports also indicate high levels of SEB in
nasal/sinus secretions of patients with chronic sinusitis,
especially in those with polyposis [22]. The present data
also showed nasal/sinus polyposis in 43.75% UC-CRS
patients. Thus, it is quite possible that the SEB-containing
secretions released from sinuses were swallowed and
contribute to the pathophysiological changes in the
colonic mucosa. The two groups of patients were treated
with approximately the same remedies for their UC dur-
ing the 12-week observation period. The different out-
come between the two groups of patients that supports
our hypotheses that CRS derived SEB plays a certain role
in the pathogenesis of UC in these patients. However, the
present data show that not all patients with S. aureus-
infected CRS suffer from UC (Figure 9). Additional factors
such as adjuvants may be required to act synergistically
with SEB to induce intestinal disorders [27].
Serum IgE antibody level elevation is one of the main fea-
tures of the type I allergic reactions including acute and
chronic allergic diseases [39,40]. The accumulated evi-
dence has emphasized that IgE mediated inflammation
plays a role in the pathogenesis of ulcerative colitis
[41,42]. We detected high levels of total serum IgE in the
UC-CRS patients in this study. This phenomenon stresses
that IgE mediated disorders are occurring in these
patients. Further evidence we have obtained is that high
levels of serum SEB specific IgE antibody were detected in
the patients with UC-CRS. Although the antigen SEB that
induced the specific IgE production in the present study
could be from multiple sources, the fact that a significant
reduction of serum SEB specific IgE after FESS indicates
that the sinusitis derived SEB may be the obligate antigen.
These SEB molecules are also capable of acting as superan-
tigens and reacting with T lymphocytes, inducing massive
activation, proliferation, and cytokine production by
CD4+ T cells via specific Vbeta elements on the TCR, ini-
tiating inappropriate immune reactions in the local tissue
and leading to IgE antibody production as well as inflam-
mation [43].
We have located anti-SEB antibody positive stained cells
in the colonic biopsies. The positively stained cells were
identified in the patients with UC-CRS, but not in the
SEB content in sinus wash fluids (nasal lavage fluids for the  groups of UC-only and healthy controls) Figure 9
SEB content in sinus wash fluids (nasal lavage fluids for the 
groups of UC-only and healthy controls). Bars stand for SEB 
content. Data were presented as mean ± SD. *, p < 0.05, 
compared with the same group at week 0. CRS-only: a group 
of 12 patients with CRS but not UC. CRS-Pol: a group of 12 
patients with CRS and nasal polyposis.
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normal colonic mucosa. The phenomenon indicates that
there are anti-SEB antibody-bearing cells in the colonic
mucosa of these patients. These cells can be the anti-SEB
antibody secreting cells (such as plasma cells), or the cells
(e.g., mast cells) have been bound by anti-SEB antibodies
that are sourced from other cells. We may employ double-
antibody staining technique with confocal microscopy in
the future to identify the cell types. How have these anti-
SEB antibody secreting cells been generated in the colonic
mucosa? The mechanism of IgE production induced by
SEB is also not clear. SEB from S. aureus is discharged to
the nasal cavity from the sinuses, swallowed into the gas-
trointestinal tract, where the SEB is absorbed by the intes-
tinal epithelial cells via a Toll like receptor (TLR) 2-
mediated mechanism. Follicle cells in the Peyer's patch
may be one of the paths to transport SEB from the luminal
side to the lamina propria. TLR2 has been identified on
the M cells of Peyer's patches in intestinal mucosa (44).
SEB is one of the ligands for TLR2 (45). Once binding to
TLR2 on the M cells, SEB may be internalized and trans-
ported across the thin cytoplasm of the M cells. SEB is
then released by exocytosis from the basolateral
membrane where the SEB can contact immune cells and
induce inappropriate immune reactions, such as IgE pro-
Mast cells in the colonic mucosa Figure 10
Mast cells in the colonic mucosa. Representative electron photomicrographs of mast cells were taken from the colonic 
mucosal specimens of A: normal controls, B: patients with UC-only and C and D: patients with UC-CRS (C, before stimulated 
with SEB; D, after stimulated with SEB). ×3,000.
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duction and inflammation. However, the detailed mecha-
nism needs to be further understood. SEB then acts as a
specific antigen and contacts immune cells in the lamina
propria to initiate antibody production. Although this is
the first study that reports anti-SEB positive immune cells
in the colonic mucosa, there are some studies involved
The ratio of mast cell degranulation in the colonic mucosa Figure 11
The ratio of mast cell degranulation in the colonic mucosa. Under an electron microscope, mast cell degranulation was catego-
rized into piecemeal degranulation (PMD) and anaphylactic degranulation (AND). Percentage of degranulation was calculated 
with the number of total granules and the number of PMD or AND. Student t test was performed with the data between 
groups. *, P < 0.05, compared with PMD of normal group (A). #, p < 0.05, compared with PMD of normal group (B). $, p < 
0.05, compared with AND of the normal group (A). &, p < 0.05, compared with AND of the normal group (B). @, p < 0.05, 
compared with PMD of UC only group (A). +, p < 0.05, compared with AND of UC only group (B).
Tryptase and histamine release from the colonic mucosal biopsy specimens in healthy controls, patients with UC-only and  patients with UC-CRS Figure 12
Tryptase and histamine release from the colonic mucosal biopsy specimens in healthy controls, patients with UC-only and 
patients with UC-CRS. Bars represent contents of tryptase (A) or histamine (B) in the supernatant of the culture of the colonic 
biopsies. * and #, p < 0.05, compared with the normal control samples; $, p < 0.05, compared with UC-only patients.
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with SEB-colonic mucosa interaction have been pub-
lished. Lu et al report that SEB compromises mouse
colonic epithelial barrier function and induces inflamma-
tion in the mucosa [19,20]. McKay et al indicate that SEB
induces colonic epithelial barrier deficiency via induction
of IFN-γ and TNF-α production that can be partially inhib-
ited by TGF-β [9,24,46]. Dionne et al observed that
colonic biopsy specimens from UC patients produce TNF-
α significantly more than normal controls in response to
SEB stimulation [17]. Taken together, these findings sug-
gest SEB plays an important role in the pathogenesis of
chronic inflammatory intestinal disorders. The precise
mechanism needs to be further investigated.
We have detected serum C reactive protein levels increas-
ing in the patients with UC of both groups. The C reactive
protein levels dropped significantly in the patients with
UC-CRS after FESS. C reactive protein is an indicator of
body inflammation and although it is non-specific,
general elevation of serum C reactive protein in UC
patients has been reported [47]. C reactive protein can be
a biochemical marker that is useful to stratify patients
likely to respond to biologic therapies and to follow
response to treatment. The decrease of serum C reactive
protein levels may be from the removal of inflammation
in the sinuses [48] or from the amelioration of UC or
both. Therefore, the decrease of serum C reactive protein
can be a useful biological marker of removing inflamma-
tion from the sinuses and amelioration of the inflamma-
tion in colonic mucosa.
Mast cells play an important role in pathology and patho-
physiology of UC [49]. The accumulated evidence shows
activated mast cells in the colonic mucosa of the UC
patients [49,50]. Our results are in line with previous
reports. Furthermore, we provided quantitative data
about mast cell activation by showing a significant differ-
ence in the ratio of degranulation in the mast cells of the
patients with UC-CRS from the patients with UC only and
the normal controls. Two types of mast cell degranulation,
PMD and AND, were identified in the present study. PMD
often presents in mast cells during chronic inflammation
whereas AND is more likely in mast cells in acute situation
such as in anaphylaxes [51]. In this study, electron micro-
scopy revealed that even in the normal colonic mucosa
there are a certain number of degranulated granules in the
mast cells including both PMD and AND according to the
criteria reported by Crivellato [52]. Most the degranulated
granules in the mast cells from the UC patients were of the
PMD type. This supports the definition that PMD type
degranulation mainly attributes to chronic inflammation
[51]. The incubation with SEB further increased mast cell
degranulation in the colonic biopsy specimens with AND
dominantly in the UC-CRS group. The mechanism of this
phenomenon may be that the anti-SEB antibody belongs
to the IgE class per se; anti-SEB IgE antibody bound to mast
cells through the high affinity IgE receptors (FcåRI); SEB
binds to the anti-SEB antibody-IgE receptor complex to
activate mast cells.
Mast cells function as effector cells during immune
inflammation by releasing chemical mediators. Hista-
mine and tryptase are two of the main mediators and play
important roles in both allergic inflammation and
chronic inflammation [53,54]. The present study shows
mast cell activation in colonic biopsies in response to SEB
stimulation ex vivo by showing release of both tryptase
and histamine, is consistent with previous reports [17].
The results implicate that when CRS-derived SEB arrives in
the colon of these patients with UC-CRS, it will disturb
intestinal mucosal function as described below. Tryptase
is the main cytosol protein of mast cells, representing
approximately 25% of the protein in mast cells [49]. A
unique feature of tryptase is its ability to cleave and acti-
vate PAR2 receptors on several cell types including intesti-
nal epithelial cells [53]. Intestinal epithelial barrier
function may be compromised in response to PAR2 acti-
vation [55]. It may contribute partially (if not totally) to
the deficiency of the intestinal barrier of patients with UC
[56]. The fact that SEB induces tryptase and histamine
release from the colonic biopsy specimens of the UC-CRS
patients, but not from the UC-only patients or normal
controls indicates that tryptase and histamine release is
specific. One possible explanation for this is that the mast
cells in the colonic mucosa have been primed by pre-
binding with anti-SEB IgE antibody. The primed mast
cells are then activated when they are re-exposed to SEB.
Yet further investigation needs to be done to clarify the
mechanism. Supporting evidence observed in the present
study is that further increase in AND type degranulation
in the mast cells of the colonic mucosa of the patients with
UC-CRS after incubation with SEB implicates that the
mast cells have had acute release of the granular contents
within a short time in contrast of PMD type degranula-
tion, the chronic release of the granular content [36,51].
The amount of tryptase and histamine released from the
UC-only biopsies after incubation with SEB didn't show
statistical difference from that before the addition of SEB
that indicates only a spontaneous mediator released from
these mast cells in the colonic tissue.
Conclusion
We have reported a group of patients with both UC and
CRS whose UC clinical symptoms were marked improved
in addition to the amelioration of CRS after FESS. These
data show a possible association between CRS and UC.
There may be a subset of UC patients with high levels of
IgE some of which is directed towards SEB. Although the
present data are not sufficient to draw a conclusion on
whether this is the initiating factor in UC or the progres-BMC Gastroenterology 2005, 5:28 http://www.biomedcentral.com/1471-230X/5/28
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sion factor, certainly it is a clue for us to further explore
pathogenesis of UC about that we have had very limited
knowledge yet.
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